PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-3.88%
Both companies show declining cash positions (-3.88% vs AVXL's -0.09%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-3.88%
Cash + STI yoy ≥ 1.5x AVXL's -0.09%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.86%
Higher Other Current Assets Growth compared to AVXL's zero value, indicating worse performance.
-4.12%
≥ 1.5x AVXL's -0.03%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-3.46%
Both AVXL and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Non-Current Assets Growth compared to AVXL's zero value, indicating worse performance.
-3.14%
Both AVXL and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-4.09%
≥ 1.5x AVXL's -0.03%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
36.45%
Above 1.5x AVXL's 18.81%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
25.40%
Higher Short-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-55.39%
Both AVXL and the company show zero Deferred Revenue (Current) Growth.
-25.40%
Higher Other Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
32.92%
Above 1.5x AVXL's 17.51%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.34%
Less than half of AVXL's 92.27%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
4.45%
Less than half of AVXL's 17.51%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.53%
0.5-0.75x AVXL's -5.65%. Martin Whitman is wary of weaker retention or lower profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.86%
≥ 1.5x AVXL's -0.96%. David Dodd sees stronger capital base growth than competitor.
-4.09%
≥ 1.5x AVXL's -0.03%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.77%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
3.93%
Above 1.5x AVXL's 0.09%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.